Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Febrile neutropenia · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Disease-free survival · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Total mortality · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Total mortality: study reported survival significantly better with surgery and RT vs chemoradiotherapy, but no useable data; 32 participants (1 RCT, Iyer 2015 oral cavity subgroup).
1 study · 32 participants
Very low